OREANDA-NEWS. The German company has received permission for the first clinical trials of a vaccine against coronavirus infection. This was announced on April 22 by the Paul Erlich Institute.

“The Paul Ehrlich Institute, the federal institute for vaccines and biomedical medicines, approved the first clinical trial of the vaccine against COVID-19 in Germany. The permit appeared as a result of a careful assessment of the profile of potential benefits and risks for the candidate for vaccination,” the report says. It is known that scientific consultations took place with the developer of the drug BioNTech for four days. “Testing candidates for vaccines in humans is an important milestone on the path to safe and effective COVID-19 vaccines for people in Germany and abroad,” the company’s representative noted.